近日,uniQure公布了AMT-130治疗亨廷顿舞蹈症(HD)随访36个月的I/II期临床顶线数据,结果显示,达到了预设的主要终点目标,与外部对照组相比,高剂量AMT-130显著减缓了HD的疾病进展。受此利好数据鼓舞,uniQure股价昨日收盘大涨了近248%,报于47.5美元/股,创四年来新高。在两款上市产品皆商业化失利之后,目前AMT-130是市场对公司倾注最大希望的管线。之前随访24个月的...
Source Link近日,uniQure公布了AMT-130治疗亨廷顿舞蹈症(HD)随访36个月的I/II期临床顶线数据,结果显示,达到了预设的主要终点目标,与外部对照组相比,高剂量AMT-130显著减缓了HD的疾病进展。受此利好数据鼓舞,uniQure股价昨日收盘大涨了近248%,报于47.5美元/股,创四年来新高。在两款上市产品皆商业化失利之后,目前AMT-130是市场对公司倾注最大希望的管线。之前随访24个月的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.